IP Library Granted Patent US 9,884,108
Granted Patent B2
US 9,884,108 · App. 15/172,947 · Granted Feb 6, 2018

Vaccine and therapeutic delivery system

Inventors: Antonio Campos-Neto (Westborough, MA); Mark Cayabyab (San Jose, CA); Margaret Duncan (Brookline, MA)
Assignee: Forsyth Dental Infirmary for Children
A61K39/21A61K39/04A61K45/06C07K14/00C07K14/005C07K14/155C07K14/162C07K14/315C07K14/35C12N7/00C12N9/2457C12N15/74C12N15/746C12Y302/01041A61K2039/523A61K2039/542A61K2039/572C07K2319/02C07K2319/40C12N2740/15022C12N2740/15033C12N2740/16022C12N2740/16033C12N2740/16034C12N2740/16051C12N2740/16071C12N2740/16111C12N2740/16122C12N2740/16134C12N2740/16171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,884,108
App. No.
15/172,947
Granted
Feb 6, 2018
Kind
B2
Abstract

The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.

Claims (5)

1. An integrally transformed non-pathogenic, commensal bacterium that expresses a synthetic nucleic acid molecule encoding a foreign fusion polypeptide comprising a HIV T20 polypeptide inhibitor and a signal polypeptide therein, wherein the synthetic nucleic acid molecule is stably integrated into genomic DNA of the bacterium, wherein the bacterium is Streptococcus mitis , wherein the signal polypeptide is pullulanase polypeptide, wherein said bacterium expresses or secretes the HIV T20 polypeptide inhibitor/pullulanase foreign fusion polypeptide, and wherein the HIV T20 polypeptide inhibitor/pullulanase foreign fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 80.

2. The integrally transformed non-pathogenic, commensal bacterium of claim 1 , wherein the nucleic acid molecule encoding the foreign fusion polypeptide is expressed in the cytoplasm, in the cell membrane or cell wall, or exports to the cell surface of the bacterium.

3. The integrally transformed non-pathogenic, commensal bacterium of claim 1 , wherein the nucleic acid molecule encoding the HIV T20 polypeptide inhibitor/pullulanase foreign fusion polypeptide comprises SEQ ID NO: 79.

4. The foreign fusion polypeptide expressed by the integrally transformed non-pathogenic, commensal bacterium of claim 1 .

5. A method of delivering a foreign protein to an individual, comprising: contacting the integrally transformed non-pathogenic, commensal bacterium of claim 1 with tissue of the oral cavity or upper respiratory tract of the individual in an amount sufficient for colonization of said bacterium.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 18, 2018
From: FORSYTH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046376/0688 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2016
From: CAMPOS-NETO, ANTONIO; CAYABYAB, MARK; DUNCAN, MARGARET
To: FORSYTH DENTAL INFIRMARY FOR CHILDREN
Reel/Frame 039449/0806 →
Continuity (3)
Continuation 13624146 · Sep 21, 2012
Provisional Application 61538346 · Sep 23, 2011
Related Publication 20160354462A1 · Dec 8, 2016